ClinicalTrials.gg
Status unknownNCT04847102Updated Nov 18, 2021

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

A Phase 3 interventional study of SARS-CoV-2 mRNA Vaccine and Placebo in COVID-19 and SARS-CoV-2, sponsored by Walvax Biotechnology Co., Ltd.. Status unknown at 12 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by Walvax Biotechnology Co., Ltd. · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.

Planned enrollment
Largest of 12
28,000 · median 157
Started
2021
with 4 others
Phase 3
4 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
1 of 12
Walvax Biotechnology Co., Ltd.

Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one has the largest planned enrollment, is one of 5 that started in 2021, is one of 4 in phase 3, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About mRNA COVID-19 Vaccine

mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA COVID-19 Vaccine in COVID-19, or all of them as a file.
02

Study summary

Approximately 28,000 subjects will be enrolled in this trial. Eligible subjects will be stratified by age (\<60 years of age and ≥60 years of age, the proportion of elderly people ≥60 years old is planned to be ≥25%) and randomly assigned into the study group and the control group at a ratio of 1:1 (14,000 in each group) to be intramuscularly administered with the investigational vaccine or placebo in a 2-dose regimen at an interval of 28 days. The experimental vaccines will be cross-vaccinated after available data of the investigational vaccine show that expected efficacy and good safety have been achieved (i.e., subjects in the study group will be vaccinated with placebo and those in the control group will be vaccinated with the investigational vaccine in the same schedule as stated above ). After the completion of the second dose for crossover vaccination, subjects will be followed up for 12 months for safety observation. An immunogenicity subgroup (n≥3000) and a reactogenicity subgroup (n≥6000) will also be included in this trial to evaluate the humoral immunity induced by the investigational vaccine and the solicited adverse events observed within 7 days post immunization. All enrolled subjects will be followed up for the evaluation of protective efficacy as well, which will be primarily characterized by the incidence rate (person-year) of COVID-19 cases collected from 14 days after complete series. Adverse events will be collected over 0-28 days after each vaccination and serious adverse events will be collected from Dose 1 through 12 months post complete series.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2

Browse trials for

Keywords

  • SARS-CoV-2 mRNA vaccine
  • Efficacy
  • Safety
  • Immunogenicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Subjects included in this trial must meet all of the following inclusion criteria:

  1. Adults aged 18 and above (both males and females are required);
  2. Individuals who are able to understand the contents listed in the form and the procedure of this clinical trial; are able to sign the informed consent form voluntarily;
  3. Individuals who are able to communicate well with the investigator and has the ability to understand and comply with the requirements of the clinical trial;
  4. Individuals who are at risk of SARS-CoV-2 infection or are exposed to COVID-19 due to regional, occupational, activity and environmental factors;
  5. For female participants of , effective should be used within 2 weeks prior to participation in this study and the pregnancy test results is required to be negative (those with amenorrhea of at least 1 year or surgical sterilization verified by medical records could be exempted from the pregnancy test). Participants should voluntarily agree to continue using at least one effective methods of contraception for 12 months after complete series (effective methods include oral contraceptives, injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.).
  6. Healthy individuals with verified medical history: individuals who are in a stable condition and whose current diseases will not worsen for at least 3 months prior to enrollment to this study.

Exclusion Criteria:

Exclusion criteria for first dose vaccination

Subjects who meet any of the following exclusion criteria shall not be enrolled:

  1. Individuals with a history of SARS-CoV-2 infection or use of any preventive products for COVID-19 (e.g., a history of any SARS-CoV-2 vaccines that have or have not been marketed);
  2. Individuals with SARS-CoV-2 etiological testing (RT-PCR Assay) (individuals with serological testing showing positive IgG and/or IgM antibodies may be enrolled);
  3. Individuals with a previous history of severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and other human coronavirus infections or diseases;
  4. Individuals who have fever within 72 hours prior to Dose 1 in this trial (oral temperature ≥38°C);
  5. Pregnant (e.g., positive pregnancy test) or lactating females;
  6. Individuals who have plan of pregnancy or interruption of effective contraceptive methods within 3 months after the second cross-vaccination in this study;
  7. Personnel of the study site or the sponsor;
  8. Individuals with prior history of allergic reaction or anaphylaxis to any vaccine or drug, e.g., , urticaria, serious eczema, dyspnea, laryngeal edema, and angioedema etc.;
  9. Individuals who have been vaccinated with any vaccine other than the vaccine used in this clinical trial from 28 days prior to Dose 1 to 28 days after Dose 2;
  10. Individuals who have participated in or plan to participate in other drug clinical trials form 28 days prior to Dose 1 to 12 months after Dose 4 (the second dose of cross-vaccination) in this study;
  11. Individuals who have hereditary hemorrhagic tendency or coagulation dysfunction (e.g., cytokine defects, coagulation disorders or disorder), or a history of significant bleeding, or a history of injury caused by intramuscular injection or venipuncture;
  12. Individuals who are confirmed for diseases affecting immune system function, including cancer (except skin basal cell carcinoma), congenital or acquired immunodeficiency (e.g., infection with (HIV)), and uncontrolled disease, based on known history or diagnosis;
  13. Individuals who have asplenia or functional asplenia;
  14. Individuals with long-term use (continuous use ≥14 days) of or other immunomodulatory drugs (e.g., : prednisone or similar drugs) within 6 months prior to Dose 1. Drugs for topical use (e.g., ointment, eye drops, inhalants or nasal spray) are allowed in this study, and the topical medications should not exceed the recommended dose in the labels for use or induce any signs of systemic exposure;
  15. Individuals who have received immunoglobulin and/or blood products within 3 months prior to Dose 1;
  16. Individuals who are suspected or known to have alcohol dependency problems or drug abuse that may affect safety evaluation or subject's compliance;
  17. Individuals who plan to permanently relocate from the local area before the completion of the study or leave the local area for long periods during the study visits;
  18. Other circumstances considered by the investigator as inappropriate to participate in the study.

Criteria for Postponement of the Subsequent Doses:

If the subjects have any of the followings prior to the subsequent doses, vaccination will be postponed. During the same immunization schedule, the second dose of vaccine will be administered at the 28th day after the first vaccination, with a time window of +5 days:

  1. Fever within 72 hours prior to the subsequent doses (oral temperature ≥38°C, probability of SARS-CoV-2 infection shall be excluded);
  2. In case of acute diseases prior to the subsequent doses, the investigator shall exclude the probability of SARS-CoV-2 infection and evaluate the likelihood of short-term recovery for the diseases;

Exclusion Criteria for the Subsequent Doses:

If the subject has any of the followings prior to the subsequent doses, the vaccination shall be terminated for the subject while other study procedures could be continued at the discretion of the investigators:

  1. Female subjects of childbearing potential who have positive pregnancy test results;
  2. Subjects who have a serious allergic reaction or serious adverse event causally related to vaccination after previous vaccination;
  3. Other circumstances considered by the investigator as inappropriate to receive the subsequent doses of the vaccine.

Criteria for Withdrawal from the Study

  1. Subjects experience disability, life-threatening adverse events or serious adverse events and have to prematurely withdraw from this study due to treatment or other reasons.
  2. Subjects are placed at safety risks by their health conditions which prevent them from continuing to participate in this study.
  3. Female subjects become pregnant during the study (if at least one dose has been administered, the subject is not required to withdraw from this study but should not receive the subsequent doses. Moreover, subsequent observation and follow-up visits should be continued);
  4. Subjects actively request to withdraw from the study;
  5. Subjects are considered unsuitable for continuing to participate in this study at the discretion of the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28,000 participants (estimated)

Study arms

  • Experimental
    Study group

    Biological: SARS-CoV-2 mRNA Vaccine · Biological: Placebo

  • Placebo comparator
    Control group

    Biological: SARS-CoV-2 mRNA Vaccine · Biological: Placebo

Interventions

  • The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection. Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2. The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains: 15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000).

  • BiologicalPlacebo

    0.9% sodium chloride solution, 0.5 mL/vial

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint as measured by the incidence rate (person-year) of COVID-19 cases

    The incidence rate (person-year) of COVID-19 cases collected from 14 days after complete series in subjects aged 18 years and above.

    Time frame: From 14 days after complete series

  2. Primary safety endpoint as measured by the incidence rates of adverse events

    Incidence rates of adverse events observed for all subjects within 28 days post each vaccination;

    Time frame: Within 28 days post each vaccination

  3. Primary safety endpoint as measured by the incidence rates of serious adverse events

    Incidence rates of solicited adverse events observed for subjects included in the reactogenicity subgroup within 30 minutes and at 7 days post each vaccination.

    Time frame: At 7 days post each vaccination

Secondary outcomes

  1. Secondary efficacy endpoint as measured by the incidence rate (person-year) of severe and critical COVID-19 cases

    The incidence rate (person-year) of severe and critical COVID-19 cases collected from 14 days after complete series in subjects aged 18 years and above;

    Time frame: From 14 days after complete series

  2. Secondary efficacy endpoint as measured by the incidence rate (person-year) of COVID-19 cases resulting in deaths

    The incidence rate (person-year) of COVID-19 cases resulting in deaths collected from 14 days after complete series in subjects aged 18 years and above;

    Time frame: From 14 days after complete series

  3. Secondary efficacy endpoint as measured by the incidence rate (person-year) of COVID-19 cases post 1 dose of vaccination

    The incidence rate (person-year) of COVID-19 cases collected from 14 days collected after Dose 1 in subjects aged 18 years and above who fail to be administered with Dose 2 for personal reasons.

    Time frame: From 14 days after Dose 1

  4. Secondary safety endpoint as measured by the incidence rate of serious adverse events

    Incidence rates of serious adverse events observed for all subjects from Dose 1 through 12 months after complete series.

    Time frame: From Dose 1 through 12 months after complete series

07

Study locations

12 of 12 sites recruiting
  • Persahabatan Hospital
    Jakarta, Indonesia
    Recruiting
    • Erlina Burhan, Dr. · Principal investigator
  • Puskesmas Duren Sawit
    Jakarta, Indonesia
    Recruiting
    • Dina Wijayanti, Dr. · Principal investigator
  • Puskesmas Kalideres
    Jakarta, Indonesia
    Recruiting
    • Linda Lidya · Principal investigator
  • Puskesmas Kebayoran Lama
    Jakarta, Indonesia
    Recruiting
    • Julianna R Amaliah, Dr. · Principal investigator
  • Puskesmas Pulogadung
    Jakarta, Indonesia
    Recruiting
    • Titta G Salim · Principal investigator
  • Centro de Investigación Clínica del Pacifico S.A. de C.V. (CICPA)
    Acapulco, Mexico
    Recruiting
    • Rafael A Rivero, Dr. · Principal investigator
  • Centro de Investigación y Avances Médicos Especializados (CIAME)
    Cancun, Mexico
    Recruiting
    • Alejandro JM Carvajal, Dr. · Principal investigator
  • Centro de Especialidades Médicas Aplicadas
    Mexico city, Mexico
    Recruiting
    • José A Vázquez, Dr. · Principal investigator
  • Instituto Nacional de Pediatría (INP)
    Mexico city, Mexico
    Recruiting
    • Miguel Ángel Rodríguez Weber, Dr. · Principal investigator
  • Oaxaca site management organization (OSMO)
    Oaxaca, Mexico
    Recruiting
    • Andrea AC Dominguez, Dra. · Principal investigator
  • Asociación Mexicana para la investigación clínica, A.C. (AMIC)
    Pachuca, Mexico
    Recruiting
    • Joselito H Pichardo, Dr. · Principal investigator
  • Oncológico Potosino
    San Luis Potosi, Mexico
    Recruiting
    • Arturo O Alvarez, Dr. · Principal investigator
08

References and documents

Publications

  • Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, Huang YJ, Zheng Y, Chen J, Ying B, Xiang Z, Shi J, Zhao J, Huang Z, Qin CF. Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults. Cell Res. 2022 Aug;32(8):777-780. doi: 10.1038/s41422-022-00681-3. Epub 2022 Jun 14. No abstract available. PubMed 35701541 ↗
  • Zhang NN, Zhang RR, Zhang YF, Ji K, Xiong XC, Qin QS, Gao P, Lu XS, Zhou HY, Song HF, Ying B, Qin CF. Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. Cell Res. 2022 Apr;32(4):401-403. doi: 10.1038/s41422-022-00626-w. Epub 2022 Feb 14. No abstract available. PubMed 35165421 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Nov 2021, 4 months after the start.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 15, 2021
StartActual
Jul 22, 2021
Primary completionEst.
Nov 30, 2021
CompletionEst.
May 30, 2023
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04847102
Lead sponsor
Walvax Biotechnology Co., Ltd.
Collaborators
Abogen Biosciences Co. Ltd., Yuxi Walvax Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 15, 2021
Start date
Jul 22, 2021
Primary completion
Nov 30, 2021 (estimated)
Completion
May 30, 2023 (estimated)
Last update
Nov 18, 2021

Study contacts

Shuyuan Yang
Contact
ynwsysy@walvax.com
+86 18687832269

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion